IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing

Liquid biopsy testing is a new laboratory-based method that detects tumour mutations in circulating free DNA (cfDNA) derived from minimally invasive blood sampling techniques. Recognising the significance for clinical testing, in 2017, IQN Path provided external quality assessment for liquid biopsy...

Descripción completa

Detalles Bibliográficos
Autores principales: Deans, Zandra C., Butler, Rachel, Cheetham, Melanie, Dequeker, Elisabeth M. C., Fairley, Jennifer A., Fenizia, Francesca, Hall, Jacqueline A., Keppens, Cleo, Normanno, Nicola, Schuuring, Ed, Patton, Simon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581928/
https://www.ncbi.nlm.nih.gov/pubmed/31028539
http://dx.doi.org/10.1007/s00428-019-02571-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581928/
https://www.ncbi.nlm.nih.gov/pubmed/31028539
http://dx.doi.org/10.1007/s00428-019-02571-3

Ejemplares similares